New Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease

Posted by on Sep 5, 2012 in Health/Research | 0 comments

… Moving Closer to a Cure? 

ImmusanT Logo, photo courtesy of ImmusanT
Would you like to be able to “resume a normal diet and return to good health”? ImmusanT, a privately-held biotechnology company whose main focus is on restoring tolerance to gluten in people with celiac disease, is working to make this a reality. ImmusanT announced yesterday, September 4, 2012, “it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2®, the first therapeutic vaccine for patients with celiac disease.” 

To date, there is no cure for celiac disease, which affects approximately one percent of the world’s population. This number doesn’t include those who live with gluten-intolerance or gluten-sensitivity. Currently, the only way to manage celiac disease, an auto-immune disorder that affects and damages the small intestine when gluten is consumed, is a strict elimination diet. Gluten is found in wheat, rye, barley and triticale.    

The thought that one day a vaccine would be available that would ultimately mitigate, or even eliminate, the need for a gluten-free lifestyle, and all the challenges, complications,   time, expense and frustrations that accompany the undiagnosed patient, could create a complete paradigm shift to one’s life and livelihood. I anxiously await the new findings.

To learn more about this study, click here.

What are your thoughts on a vaccine to establish gluten tolerance?    

 Safe food is a journey … Thrive!™

Leave a Reply

Your email address will not be published. Required fields are marked *